Methods for treatment with bucindolol based on genetic targeting
US8916603B2 · kind B2 · utility
0Cited by
39References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2011 |
| Grant date | Dec 23, 2014 |
| Priority date | — |
| Expiry date | Dec 1, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.